Lindner Nils, Blaeser Andreas
BioMedical Printing Technology, Department of Mechanical Engineering, TU Darmstadt, Darmstadt, Germany.
Centre for Synthetic Biology, TU Darmstadt, Darmstadt, Germany.
Front Bioeng Biotechnol. 2022 May 20;10:855042. doi: 10.3389/fbioe.2022.855042. eCollection 2022.
Biofabrication, specifically 3D-Bioprinting, has the potential to disruptively impact a wide range of future technological developments to improve human well-being. Organs-on-Chips could enable animal-free and individualized drug development, printed organs may help to overcome non-treatable diseases as well as deficiencies in donor organs and cultured meat may solve a worldwide environmental threat in factory farming. A high degree of manual labor in the laboratory in combination with little trained personnel leads to high costs and is along with strict regulations currently often a hindrance to the commercialization of technologies that have already been well researched. This paper therefore illustrates current developments in process automation in 3D-Bioprinting and provides a perspective on how the use of proven and new automation solutions can help to overcome regulatory and technological hurdles to achieve an economically scalable production.
生物制造,特别是3D生物打印,有可能对未来广泛的技术发展产生颠覆性影响,以改善人类福祉。芯片上的器官可以实现无动物和个性化的药物开发,打印器官可能有助于克服无法治疗的疾病以及供体器官的短缺,而培养肉可能解决工厂化养殖对全球环境造成的威胁。实验室中高度的体力劳动加上训练有素的人员稀缺,导致成本高昂,并且目前严格的法规常常阻碍那些已经得到充分研究的技术商业化。因此,本文阐述了3D生物打印过程自动化的当前发展情况,并就如何使用成熟的和新的自动化解决方案有助于克服监管和技术障碍以实现经济上可扩展的生产提供了一个视角。